Abbott has entered a licensing and supply agreement with Zydus Cadila of India for a portfolio of pharmaceutical products that Abbott will commercialize in 15 emerging markets. Abbott will gain rights to at least 24 products in 15 emerging markets. The agreement also includes an option for the addition of more than 40 Zydus products to the collaboration. These products include indications for pain, cancer and cardiovascular, neurological and respiratory diseases. The partnership will leverage Ab...